May 10th 2024
From Big Pharma to biotech—and a globe-spanning journey along the way—Yvonne Greenstreet, this year’s Healthcare Businesswomen’s Association Woman of the Year, is right where she wants to be: leading efforts to advance “bold ideas” in RNAi therapeutics into life-changing gains for patients.
Bringing New Solutions into View for Cell and Gene Therapies: Masahide Goto, President, AIRM
January 31st 2022Masahide Goto outlines the world of the Astellas Institute for Regenerative Medicine (AIRM), which serves as the company’s global hub for regenerative medicine and cell therapy research and manufacturing in ophthalmology and other therapeutic areas that have few or no available treatment options.
Breaking New Ground in Biopharma
January 11th 2022Myrtle Potter is no stranger to overcoming adversity. As CEO of Sumitovant Biopharma, she has used her entrepreneurship, determination, and inclusive attitude to help her persevere and achieve her highest goals while overseeing five companies—Myovant, Urovant, Enzyvant, Altavant, and Spirovant.
Avoiding the Shiny Penny Syndrome of Digital Transformation
November 4th 2021Chris Doerr, Senior Vice President, Global Generic Sourcing, AmerisourceBergen, talks about the importance of companies taking an honest view of their current-state capabilities when embarking on the digital transformation journey.
A New Level of Immunology: Sanjay Shukla, aTyr Pharma
September 30th 2021aTyr Pharma’s Dr. Sanjay S. Shukla talks about how his background in biostatistics, informatics and medicine is helping him and his team of researchers and scientists develop meaningful new medicines in a novel area of immunobiology, by looking at pathways where other drugs may have failed.
Protecting Public Health: Lorna Meldrum, Seqirus
September 28th 2021Lorna Meldrum, Vice President, Commercial Operations, International Markets & Pandemic at Seqirus, talks about the challenges of the influenza vaccine market and how COVID-19 has highlighted that preventing ’flu is crucial for public health.
Setting Sights on the COVID Vaccine Market: Shankar Musunuri, CEO, Ocugen
September 27th 2021Dr. Shankar Musunuri talks about his 25 years’ experience in biotech about his company Ocugen’s latest mission to develop, manufacture, and commercialize Bharat Biotech’s COVID-19 vaccine, COVAXIN, in the North American market.